How to Read a Peptide Certificate of Analysis, Field by Field

A certificate of analysis is the one document that travels with a research peptide — material supplied for research use only, not for human or animal consumption — and it's routinely read as a single number. Someone glances at the purity line, sees 98%, and stops. That line is real. But it answers a narrower question than most readers assume, and it sits on a page full of fields that answer the questions it doesn't.

That page is also the only physical evidence about what's in the vial. Reading it field by field is the difference between trusting a claim and understanding one. What follows walks the document from the header block down to the impurity profile.

What a Certificate of Analysis Is — and What It Isn't

Start with what the document actually claims. A certificate of analysis is a laboratory's record of what it measured on one specific lot, checked against a written specification. It isn't a general quality rating, it isn't a safety clearance, and it says nothing about any lot other than the one named.

The structure isn't arbitrary either. In the regulated pharmaceutical setting, ICH Q6B is the framework specifications document for peptide and protein quality, covering appearance, identity, purity and content. A companion guideline, ICH Q2(R2), governs validation of the procedures that produce each figure — so the method behind a number is formally part of the specification. A result and the procedure behind it are one claim.

Research-grade material isn't held to that package, which is exactly why reading the fields matters: the framework describes what a complete analytical picture looks like, and any certificate can be held up against it. Three questions organize the rest of the page. Is this the right molecule? How much of the peptide-related material is the target sequence? And how much of the vial's weight is peptide at all?

The Header Block: What the Top of the Page Commits To

Before any instrument result appears, the header makes claims you can check arithmetically and against the vial in your hand.

Product name and sequence. The amino acid sequence is the actual definition of the product; the compound or trade name is a label for it. If the two disagree, the sequence is what was tested.

Molecular formula and molecular weight. Many certificates report two molecular weights — one for the free base, one for the salt form. Pick the wrong one and the error propagates quietly into every concentration calculation downstream.

Lot or batch number. The most under-read field on the page. A certificate describes one lot; if the number doesn't match the vial label, the document describes different material, however good its numbers look. It's also where batch-to-batch consistency testing comes in, since consistency is a property of a series of lots, not of any single page.

Date of analysis, and retest or expiry date. Date of manufacture and date of analysis aren't the same thing. A purity figure is a snapshot of the lot when it was tested.

Appearance and storage conditions. Easy to dismiss, but ICH Q6B lists visual inspection as a real specification line alongside the instrumental tests.

The Identity Block: Proving the Molecule Matches the Label

Identity testing answers one question: is this the sequence printed in the header? No single method answers it completely, which is why a good certificate shows two or more.

Mass Spectrometry: Observed Versus Theoretical Mass

The field shows a theoretical molecular weight next to an observed value, most often from electrospray ionization. ESI is a soft ionization method, so large molecules survive intact instead of shattering — what you want when identity is the thing being measured. It also tends to produce multiply-charged ions, which lowers the apparent mass-to-charge ratio, so the instrument reports m/z rather than raw mass.

The comparison is the test. In reference-standard work on leuprolide, the experimental m/z was 1209.6515 against a theoretical 1209.6533 — agreement at the fourth decimal place. One caveat belongs next to any mass result: a matching total mass confirms composition, not order. Two arrangements of the same residues weigh exactly the same. Where that isn't enough, fragmentation-based sequence verification fills the gap, and peptide mapping is the orthogonal approach.

Retention-Time Match Against a Reference Standard

The criterion is simple: the sample's main peak leaves the column at the same retention time as a reference standard, and the two analysed together give a single peak rather than two. It's comparative, so it's only as good as the standard behind it.

Amino Acid Analysis and Chirality

Why run amino acid analysis when mass spectrometry has already confirmed the mass? Because leucine and isoleucine are isomers of identical mass, and only residue-ratio analysis separates them. In bivalirudin reference material, isoleucine measured 0.97 and leucine 0.94 against a theoretical 1.0.

D-amino acids pose the same problem for stereochemistry — identical mass, identical sequence, different molecule — resolved by chiral GC-MS. That same bivalirudin work showed roughly 50% of its phenylalanine in the D-form, which was the intended design rather than a defect.

Reading the HPLC Purity Field

The most useful thing to know about the purity percentage: it isn't a measure of how much peptide is in the vial. It's the main peak's share of everything the detector saw.

What the Instrument Actually Does

Reversed-phase HPLC runs a polar, mostly aqueous mobile phase through a nonpolar packing material under pressure. Separation turns on hydrophobicity: molecules that prefer the packing to the solvent come off later. The output is a chromatogram — detector signal against time — in which each component appears as a peak at its characteristic retention time, and a peak's area is proportional to how much of that component is present.

How the Percentage Is Calculated

The figure comes from area normalization: main peak area divided by total detected peak area. Reference-standard documentation describes it exactly that way — percent of total detected area, produced by the monograph RP-HPLC method with a specified column chemistry, temperature and wavelength. Detection is typically UV absorbance at 220 nm, which picks up the amide bonds of the peptide backbone.

Three Reasons the Same Material Can Report Different Purities

Anything the detector can't see never enters the denominator. Salt, water and non-absorbing residue are effectively invisible at 220 nm, so they neither add to nor subtract from the percentage. That's the field's defining limitation.

Co-elution. An impurity that leaves the column at the same moment as the target sequence gets counted inside the main peak. Gradient, column chemistry and temperature all change what separates from what — which is why published methods specify defined column parameters.

Wavelength. Change the detection wavelength and you change how strongly impurities respond relative to the main peak, which changes the ratio.

Hence a practical rule: a purity figure stripped of its method parameters isn't a conservative number. It's an uninterpretable one.

Purity and Net Peptide Content Are Not the Same Number

Two fields answer two different questions, and conflating them is the most common misreading of a peptide analysis. They are two different numbers by construction.

Chromatographic purity asks: of the peptide-related material the detector saw, what fraction was the target sequence? Net peptide content, sometimes reported as mass-balance purity, asks: of the vial's total weight, what fraction is peptide? Published methodology measures every detectable impurity class — peptide-related impurities, counterions, water, residual solvents and inorganic residue — and subtracts all of them from 100%.

The gap isn't theoretical. In one reference-material characterization, acetic acid alone accounted for 5.58% w/w, against 0.003% w/w for TFA. Add the water content typical of a lyophilized solid and the divergence is substantial even when chromatographic purity is excellent.

So the rule follows directly. If a certificate reports chromatographic purity and nothing else, the amount of peptide by weight is unstated. Not implied, not approximated — unstated.

The Mass-Balance Fields: Water, Counterion, Solvents, Residue

These four fields account for the part of the vial that isn't peptide. They're what turn a purity percentage into an actual quantity.

Water Content

Water is measured by coulometric Karl Fischer titration, which works because iodine oxidizes sulfur dioxide in the presence of water in a strict one-to-one molar relationship. That stoichiometry is what makes the method quantitative rather than comparative, and the coulometric variant resolves from roughly 1–5 ppm up to about 5% water — the right window for a dried solid.

Water matters twice over: residual moisture both inflates the apparent mass of peptide and bears on storage stability. It also drifts with handling, which is why careful practice measures it at the time of preparation.

Counterion Content

This field exists because of how the molecule was built. Solid-phase synthesis uses trifluoroacetic acid for deprotection and for cleaving the peptide from the resin, so the material arrives as a salt; acetate is commonly exchanged in afterwards as the less problematic counterion. Both acids are quantified by dedicated HPLC methods, so residual TFA quantification is a named test in its own right, separate from the purity assay.

Residual Solvents and Residue on Ignition

Residual solvent testing by gas chromatography quantifies production-related organic residues; residue on ignition captures inorganic impurities by thermal analysis. Neither shows up in a 220 nm chromatogram, which is the point.

The Impurity Profile, and the Thresholds Regulators Apply

Impurities on a peptide certificate aren't generic contamination. They're specific, predictable products of how the molecule was assembled and how it has been stored.

FDA's synthetic peptide framework splits them in two. Process-related impurities come from manufacturing — leachables and extractables, microbial contaminants, host-cell proteins. Peptide-related impurities are defects in the peptide itself: deletion and duplication sequences, incomplete coupling products, and from storage, methionine oxidation, cysteine dimerization, and the broader oxidation, deamidation and hydrolysis pathways.

For a sense of scale, the pharmaceutical setting supplies a hard number. FDA's position on synthetic peptide generics is that any new peptide-related impurity not present in the reference product should sit at no more than 0.5 percent of the drug substance, since higher levels raise potential immunogenicity questions. That threshold doesn't govern research-grade material, but it's useful context for what counts as small — and it explains why orthogonal methods are expected rather than one purity figure.

Red Flags on a Thin Certificate

What's missing from a certificate is as informative as what's on it, and there's published evidence that the gaps matter. One evaluation of synthetic research peptides specified at 95.0% minimum purity found that only 44% of batches met the stated purity on independent re-analysis. A checklist of absences:

• No lot number — the certificate can't be tied to the material in hand.
• No named method, column, gradient or wavelength — the purity figure has no interpretable basis.
• No chromatogram or spectrum — a transcribed conclusion with no trace to inspect for co-elution or baseline problems.
• Identity by a single method — total mass alone establishes neither sequence order nor stereochemistry.
• No water or counterion value — net peptide content is unknown, so the purity figure stands alone.
• Round numbers throughout (99%, 99.9%) with no decimals or statement of variability — inconsistent with how instruments report.

Frequently Asked Questions

What purity figure should a research peptide certificate of analysis show?

Most research-grade synthetic peptides are specified at a minimum of 95.0% chromatographic purity by reversed-phase HPLC, with reference-standard work describing typical material in the 94–98% range. The figure alone is incomplete, though. A 98% claim with no named method, column, wavelength or lot number is less informative than a 96% claim that shows all of them, because purity by area normalization depends entirely on which method produced the trace.

Why is the purity percentage different from the net peptide content?

They measure different things. HPLC purity asks what share of the detected peptide-related material is the target sequence. Net peptide content asks what share of the vial's actual weight is peptide, which means subtracting water, counterion salt, residual solvents and inorganic residue. One worked example found acetic acid alone at 5.58% w/w of a peptide reference material.

Can a certificate of analysis be wrong?

It can be incomplete, outdated or unverified, and independent re-testing has found real gaps — in one evaluation, only 44% of batches met the stated specification on re-analysis. A certificate records what one laboratory measured on one lot using one method, so its value depends on the method being named, the lot number matching the vial, and the issuing laboratory being accountable for the result.

Which fields matter most if I only read a few?

Four. The lot number, the identity result, the purity figure together with its method parameters, and the water plus counterion values — because those last two are what separate a purity percentage from the amount of peptide actually present.

Putting It All Together

A certificate of analysis is a panel, not a score. Identity establishes that the molecule is the one named. Chromatographic purity establishes what share of the peptide-related material is the target sequence. The water, counterion, solvent and residue fields establish how much peptide is physically present. Read as a single number, the document loses most of its information.

The method parameters aren't fine print either. Regulatory frameworks count the validated procedure as part of the specification, so a figure and the method behind it are one claim, not two. For the chemistry behind any individual line, the per-field explainers in the Optides research library go deeper.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.